scholarly journals Cluster analysis in prediction of biological activity and molecular structure relationship of dipeptidyl peptidase-4 inhibitors for the type two diabetes mellitus treatment

2020 ◽  
Author(s):  
Sarah Syarofina ◽  
Alhadi Bustamam ◽  
Arry Yanuar ◽  
Devvi Sarwinda ◽  
Oky Hermansyah
Keyword(s):  
Molecular Structure ◽  
Diabetes Mellitus ◽  
Cluster Analysis ◽  
Biological Activity ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Structure Relationship ◽  
Diabetes Mellitus Treatment ◽  
Type Two Diabetes ◽  
Relationship Of

scholarly journals DIABETES MELLITUS TREATMENT: A RAPID REVIEW ON INNOVATIVE THERAPIES

2019 ◽  
Vol 12 (1) ◽  
pp. 46
Author(s):  
D. Krishna Veni ◽  
N. Vishal Gupta
Keyword(s):  
Diabetes Mellitus ◽  
Type I Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Rapid Review ◽  
Type I ◽  
Pancreatic Islet Transplantation ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Innovative Therapies ◽  
Diabetes Mellitus Treatment

Diabetes mellitus is a chronic and metabolic disorder which results from defects in a section of insulin, action of insulin, or both. Primarily drugs are used to control the symptoms and save life. Secondary aims are to prevent long-term diabetic complications and by eliminating various risk factors to increase longevity. In type I diabetes mellitus, new innovative therapies such as pancreatic transplantation, pancreatic islet transplantation, stem cell therapy, transdifferentiation, and gene therapy are discussed, and regarding type II diabetes mellitus, treatment is based on drugs which stimulates the secretion of insulin such as conventional therapy, antihypoglycemic agents such as insulin, insulin secretagogues, and insulin sensitizers, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, and a list of patents for the treatment of diabetes mellitus are discussed in this review article.

scholarly journals DIABETES MELLITUS TREATMENT: A RAPID REVIEW ON INNOVATIVE THERAPIES

2019 ◽  
Vol 12 (1) ◽  
pp. 46
Author(s):  
D. Krishna Veni ◽  
N. Vishal Gupta
Keyword(s):  
Diabetes Mellitus ◽  
Type I Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Rapid Review ◽  
Type I ◽  
Pancreatic Islet Transplantation ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Innovative Therapies ◽  
Diabetes Mellitus Treatment

Diabetes mellitus is a chronic and metabolic disorder which results from defects in a section of insulin, action of insulin, or both. Primarily drugs are used to control the symptoms and save life. Secondary aims are to prevent long-term diabetic complications and by eliminating various risk factors to increase longevity. In type I diabetes mellitus, new innovative therapies such as pancreatic transplantation, pancreatic islet transplantation, stem cell therapy, transdifferentiation, and gene therapy are discussed, and regarding type II diabetes mellitus, treatment is based on drugs which stimulates the secretion of insulin such as conventional therapy, antihypoglycemic agents such as insulin, insulin secretagogues, and insulin sensitizers, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, and a list of patents for the treatment of diabetes mellitus are discussed in this review article.

scholarly journals Effects of Sitagliptin on HbA1c levels in uncontrolled hyperglycemia in diabetics using conventional OAD’s.

2020 ◽  
Vol 27 (05) ◽  
pp. 963-967
Author(s):  
Amar Nazir ◽  
Fida Muhammad Sheikh ◽  
Sheraz Saleem
Keyword(s):  
Diabetes Mellitus ◽  
Hba1c Level ◽  
Glycosylated Hemoglobin ◽  
Type Ii Diabetes Mellitus ◽  
Cross Sectional ◽  
Entire Study ◽  
Dipeptidyl Peptidase 4 ◽  
Diagnostic Center ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Hba1c Levels

Objectives: The study anticipates to appraise HbA1c levels after three months of sitagliptin addition (100mg/day) to patients already using conventional oral antidiabetics in patients of type II diabetes mellitus who have a meager retort to these existing anti diabetics. Study Design: Mainly cross sectional prospective multicenter, open labeled study. Setting: Department of Medicine University medical diagnostic center & District Head Quarter Hospital Sargodha. Period: January 2017 to June 2017. Material & Methods: 100 inadequately controlled diabetics using different types of oral anti diabetics were chosen and an especially designed performa was accomplished. In our study we gave preference to those patients who were on preexisting oral anti diabetics and now dipeptidyl peptidase 4 inhibitors were added for the first time. The patients were instructed (at the baseline visit) to report during the subsequent visit about glycemic control. Patients were not clued-up that glycosylated hemoglobin control was the main seek of the study, so there was no chance for Pygmalion effect. Results: Levels of glycosylated hemoglobin were significantly reduced after three months of treatment compared to baseline, with a mean alteration in HbA1c level from baseline of −0.77% (range, −0.68 to − -0.86%) in the entire study population at three months. The percentage of patients who achieved an HbA1c level of <6.9% significantly increased after three months of treatment, reaching 58.1%. Conclusion: HbA1c significantly lowered in patients with type 2 diabetes mellitus on conventional OADs after adding sitagliptin.

scholarly journals Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus

Antioxidants ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 233
Author(s):  
Elisabetta Bigagli ◽  
Cristina Luceri ◽  
Ilaria Dicembrini ◽  
Lorenzo Tatti ◽  
Francesca Scavone ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Propensity Score ◽  
Oxidative Damage ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

Pre-clinical studies suggested potential cardiovascular benefits of dipeptidyl peptidase-4 inhibitors (DPP4i), however, clinical trials showed neither beneficial nor detrimental effects in patients with type 2 diabetes mellitus (T2DM). We examined the effects of DPP4i on several circulating oxidative stress markers in a cohort of 32 T2DM patients (21 males and 11 post-menopausal females), who were already on routine antidiabetic treatment. Propensity score matching was used to adjust demographic and clinical characteristics between patients who received and who did not receive DPP4i. Whole-blood reactive oxygen species (ROS), plasma advanced glycation end products (AGEs), advanced oxidation protein products (AOPP), carbonyl residues, as well as ferric reducing ability of plasma (FRAP) and leukocyte DNA oxidative damage (Fpg sites), were evaluated. With the exception of Fpg sites, that showed a borderline increase in DPP4i users compared to non-users (p = 0.0507), none of the biomarkers measured was affected by DPP4i treatment. An inverse correlation between estimated glomerular filtration rate and AGEs (p < 0.0001) and Fpg sites (p < 0.05) was also observed. This study does not show any major effect of DPP4i on oxidative stress, assessed by several circulating biomarkers of oxidative damage, in propensity score-matched cohorts of T2DM patients.

Sign in / Sign up

Export Citation Format

Share Document